Nasdaq:US$15.81 (+0.12) | HKEX:HK$24.95 (-0.25) | AIM:£2.29 (-0.01)
搜索
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2014-06-03

ASCO 2014: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors